科济药业-B(02171.HK)：于2025年第22届IMS年会上呈列的赛恺泽?的研究成果更新

Core Insights - Company Kogei Pharmaceuticals-B (02171.HK) announced the long-term follow-up results of its product Zevor-cel (CT053), a targeted BCMA autologous CAR-T cell therapy, which were presented at the 22nd International Myeloma Society (IMS) annual meeting [1] Group 1 - The updated results of the Phase I clinical trial for Zevor-cel were showcased in a poster presentation at the IMS annual meeting held on September 17, 2025, in Toronto [1]